SEARCH

SEARCH BY CITATION

References

  • 1
    Tisdale MJ. Biomedicine protein loss in cancer cachexia. Science 2000; 289: 22934.
  • 2
    Argiles JM, Alvarez B, Lopez-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev 1997; 17: 47798.
  • 3
    Onuma E, Tsunenari T, Saito H, Sato K, Yamada-Okabe H, Ogata E. Parathyroid hormone-related protein (PTHrP) as a causative factor of cancer-associated wasting: Possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts. Int J Cancer 2005; 116: 4718.
  • 4
    Takahashi S, Hakuta M, Aiba K et al . Elevation of circulating plasma cytokines in cancer patients with high plasma parathyroid hormone-related protein levels. Endocr Relat Cancer 2003; 10: 4037.
  • 5
    Deans C, Wigmore S, Paterson-Brown S, Black J, Ross J, Fearon CHK. Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer 2005; 103: 181018.
  • 6
    Matsumoto T, Fujimoto-Ouchi K, Tamura S, Tanaka Y, Ishitsuka H. Tumour inoculation site-dependent induction of cachexia in mice bearing colon 26 carcinoma. Br J Cancer 1999; 79: 7649.
  • 7
    Fujimoto-Ouchi K, Onuma E, Shirane M, Mori K, Tanaka Y. Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. Cancer Chemother Pharmacol 2007; 59: 80715.
  • 8
    Fujimoto-Ouchi K, Tamura S, Mori K, Tanaka Y, Ishitsuka H. Establishment and characterization of cachexia-inducing and – non-inducing clones of murine colon 26 carcinoma. Int J Cancer 1995; 61: 5228.
  • 9
    Onuma E, Sato K, Saito H et al . Generation of a humanized monoclonal antibody against human parathyroid hormone-related protein and its efficacy against humoral hypercalcemia of malignancy. Anticancer Res 2004; 24: 266573.
  • 10
    Yin JJ, Selander K, Chirgwin JM et al . TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103: 197206.
  • 11
    Yoshida T, Sakamoto H, Horiuchi T et al . Involvement of prostaglandin E2 in interleukin-1alpha-induced parathyroid hormone-related peptide production in synovial fibroblasts of patients with rheumatoid arthritis. J Clin Endocrinol Metab 2001; 86: 32728.
  • 12
    Futaki N, Yoshikawa K, Hamasaka Y et al . NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. General Pharmacol 1993; 24: 10510.
  • 13
    Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 12540.
  • 14
    Goppelt-Struebe M, Stroebel M, Hoppe J. Regulation of platelet-derived growth factor isoform-mediated expression of prostaglandin G/H synthase in mesangial cells. Kidney Int 1996; 50: 718.
  • 15
    Wadleigh DJ, Herschman HR. Transcriptional regulation of the cyclooxygenase-2 gene by diverse ligands in murine osteoblasts. Biochem Biophys Res Commun 1999; 264: 86570.
  • 16
    Sterling JA, Oyajobi BO, Grubbs B et al . The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res 2006; 66: 754853.
  • 17
    Bizik J, Kankuri E, Ristimaki A et al . Cell-cell contacts trigger programmed necrosis and induce cyclooxygenase-2 expression. Cell Death Differ 2004; 11: 18395.
  • 18
    Tanaka Y, Tanaka T, Ishitsuka H. Antitumor activity of indomethacin in mice bearing advanced colon 26 carcinoma compared with those with early transplants. Cancer Res 1989; 49: 59359.
  • 19
    Hussey HJ, Tisdale MJ. Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model. Int J Cancer 2000; 87: 95100.
  • 20
    Peluffo GD, Stillitani I, Rodriguez VA, Diament MJ, Klein SM. Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal anti-inflammatory drugs. Int J Cancer 2004; 110: 82530.
  • 21
    Davis TW, Zweifel BS, O’Neal JM et al . Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther 2004; 308: 92934.